Date: 2016-01-07
Type of information: R&D agreement
Compound: Degronimids - targeted protein degradation (TPD) therapeutics
Company: C4 Therapeutics (USA - MA) Roche (Switzerland)
Therapeutic area:
Type agreement: collaboration R&D
Action mechanism: Degronimids link drug-like small molecules to the cellular ubiquitin/proteasome system to naturally eliminate targeted proteins by tagging them with ubiquitin for destruction by the proteasome. Degronimids are capable of hitting many more targets than protein inhibitors or peptide-based approaches, and are active against previously undruggable targets, while also reducing potential for drug resistance. This new class of targeted protein degradation (TPD) therapeutics incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). C4 Therapeutics\' Degronimid technology platform was pioneered in 2010 by researchers in the Bradner Laboratory at Dana-Farber Cancer Institute, and is exclusively licensed to C4 Therapeutics from Dana-Farber.
Disease:
Details: * On January 7, 2015, C4 Therapeutics announced that they will enter into a strategic collaboration with Roche to develop novel treatments in the field of targeted protein degradation (TPD) using C4’s Degronimid™ technology. C4’s Degronimids represent a new class of small molecules, TPD therapeutics, which target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the ubiquitin/proteasome system (UPS). Under the terms of the agreement, C4 will initially develop TPD therapeutics that utilize Degronimid technology for a specific set of target proteins. After successful completion of a defined preclinical development phase, Roche has the option to pursue further pre-/clinical development and commercialization.
Financial terms: C4 will receive an undisclosed upfront payment and additional development, regulatory and commercial milestone payments per target, as well as sales milestone payments and potential tiered royalties on sales of products resulting from the agreement. The potential value of the deal over time is greater than $750 million.
Latest news:
